Comment on "Adipose triglyceride lipase regulates eicosanoid production in activated human mast cells." by Dichlberger et al.
Inflammation is a fundamental protective response in higher eukaryotes to a variety of external stimuli such as environmental toxins, pathogens, or allergens. These stimuli are encountered by immune cells such as mast cells (MCs), which mediate the initial defense reaction against external "invaders". MCs reside throughout vascularized tissues and are especially prominent near body surfaces defining the border between external and internal environment. MCs are considered the main "effector" cells in allergic disorders and tissue remodeling. However, more recent evidence suggests that MCs are also involved in inflammatory reactions associated with obesity, atherosclerosis, autoimmune disorders, and cancer (1). MCs derive from hematopoietic stem cells, circulate and migrate as precursors, and terminally mature in their target tissues (2) . There, MCs reside as quiescent cells until activated by antigen-presenting immunoglobulin E or other non-immunological stimuli. This triggers the release of various "effector" molecules from MCs, which mediate the immune response (3). These mediators include histamine, proteases, various growth factors, and chemokines, which are stored in cytosolic granules in quiescent MCs and are acutely secreted upon activation. Additionally, MC activation triggers de novo synthesis of lipid-derived signaling molecules. The most prominent are eicosanoids comprising leukotrienes and prostaglandins, which are synthesized by lipoxygenases and cyclooxygenases (COX), respectively (4). The common precursor of all eicosanoids is the polyunsaturated omega-6 fatty acid (FA) arachidonic acid (20:4 ω6, AA).
The bulk of cellular AA is found in membrane glycerophospholipids predominantly esterified to the sn-2 position on the glycerol backbone (5). In the classical synthesis pathway for eicosanoids, phospholipases A 2 (PLA 2 ) hydrolyze the ester bond to release AA. The mammalian PLA 2 superfamily comprises more than 30 enzymes subdivided in six groups (6) .
Group IVA PLA 2 (cPLA 2 α) is considered to be the primary phospholipase for AA release in Silencing of ATGL in human MCs caused an increase in neutral lipids in LDs and a concomitant decrease in eicosanoid production similar to silencing of cPLA 2 α. ATGL belongs to a protein family of 9 members containing a "patatin" domain. Several members of this family are phospholipases, which led to the family designation patatin-like phospholipase domain-containing protein A1 to A9 (PNPLA1-9) (14) . Unlike other family members, ATGL preferentially hydrolyzes TGs playing a crucial role in TG catabolism (lipolysis) in adipose and many non-adipose tissues (15, 16) . ATGL requires a co-activator termed comparative gene identification 58 (CGI-58) for maximal TG hydrolase activity (17) . In addition to its TG hydrolase activity, ATGL also exhibits low but detectable phospholipase A 2 activity as well In MCs, additional mechanistic studies are required to clarify whether ATGLgenerated AA can be directly utilized for eicosanoid biosynthesis or whether preceding AA re-esterification into glycerophospholipids and subsequent re-release by cPLA 2 α is required before oxygenation. Additionally, it has to be shown whether the TG hydrolase of ATGL accounts for AA release in MCs -as hypothesized -or whether ATGL's minor phospholipase activity contributes to AA production. Future work will also have to address whether loss of ATGL in animals models either by genetic or pharmacologic inactivation of the enzyme affects AA release, eicosanoid production, and inflammation. ATGL-deficient mice may be employed in various inflammatory disease models such as cancer to provide further insights into the biological significance of this enzyme not only in MCs, but also in other inflammatory/immune cells. 
